Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 2121 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf 2017;40:855-69. [Ref.ID 102075]
2. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
5.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
6. Cita con resumen
Anónimo. EMA panel recommends approval of GSK’s triple inhaler to treat COPD. DIA Daily 2017:2. [Ref.ID 102050]
7. Cita con resumen
Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]
8. Cita con resumen
Goldacre B, Lane S, Mahtani KR, Heneghan C, Onakpoya I, Bushfield I, Smeeth L. Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study. BMJ 2017;358:j3334. [Ref.ID 101997]
9. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
10. Cita con resumen
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer AN. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol 2017;83:884-93. [Ref.ID 101970]
12. Cita con resumen
Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]
13.Enlace a cita original Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017:26 de marzo. [Ref.ID 101903]
14. Cita con resumen
Xu J, Emenanjo O, Ortwerth M, Lurie P. Association of appearance of conflicts of interest with voting behavior at FDA advisory committee meetings—A cross-sectional study. JAMA Intern Med 2017;177:1038-40. [Ref.ID 101664]
15. Cita con resumen
16. Cita con resumen
Anónimo. FDA announces list of off-patent drugs with no competition. DIA Daily 2017:1. [Ref.ID 101658]
17. Cita con resumen
Huang Z, Ma J. Chronic purulent nasal discharge. BMJ 2017;357:j2061. [Ref.ID 101636]
18. Cita con resumen
Al-Khateeb Z, Hadker N, Scaife JG, Miyasato G, Sanchez H. What we value: the proposition behind the price. Trinity Partners 2017:26 de mayo. [Ref.ID 101602]
19. Cita con resumen
Anónimo. EMA’s CHMP recommends approval of biosimilar insulin lispro. DIA Daily 2017:2. [Ref.ID 101598]
20. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
Seleccionar todas
 
 1 a 20 de 2121 siguiente >>